Möchten Sie immer auf dem neuesten Stand bleiben?

NEW YORK, June 11, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to...

NEW YORK, 11 juin 2026 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), société de biotechnologie de stade clinique qui utilise sa plateforme pionnière d’édition du génome pour...

Marvel Biosciences Receives Notice of Allowance for Australian Patent Application Covering Composition of Matter for its Lead Therapeutic Candidate MB-204

First-in-class oral ERAP1 inhibitor shows 13–36% ORR across 6 solid tumor types in anti-PD-1 resistant patients

Pecoy Phase 1 review highlights major gold recovery gains, strong copper recoveries and molybdenum upside at its Peru copper-gold project.

Phase 1 Clinical Data Demonstrate Dose-Proportional PK, No Dose-Limiting Toxicities Through Four Dose Levels, and Concordance with Preclinical PBPK Predictions CRANBERRY TOWNSHIP, Pa., May 11, 2026 ...

Marvel Biosciences to participate in 2nd Neuroscience Innovation Partnering & Licensing Summit, allowing Marvel to showcase its progress on global stage

Marvel Biosciences Corp. announces it has identified two lead pediatric-friendly liquid formulations of its patented lead compound, MB-204.

Marvel announces financial and strategic backing from 5 Horizons Ventures to support its upcoming Phase 1 clinical trial of patented lead asset MB-204

Dosing of the first patient in the Phase 1 clinical trial of ADCX-020.